HUMA Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -2325.37% compared to Humacyte, Inc.'s net margin of 49.9%. Humacyte, Inc.'s return on equity of -- beat CorMedix, Inc.'s return on equity of 95.25%.

Humacyte, Inc. has a consensus price target of $7.86, signalling upside risk potential of 627.51%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that Humacyte, Inc. has higher upside potential than CorMedix, Inc., analysts believe Humacyte, Inc. is more attractive than CorMedix, Inc..

Humacyte, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Humacyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Humacyte, Inc. quarterly revenues are $753K, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Humacyte, Inc.'s net income of -$17.5M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Humacyte, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte, Inc. is 98.39x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis, Inc. has a net margin of -2325.37% compared to Humacyte, Inc.'s net margin of 21.11%. Humacyte, Inc.'s return on equity of -- beat Nuwellis, Inc.'s return on equity of -1004.06%.

Humacyte, Inc. has a consensus price target of $7.86, signalling upside risk potential of 627.51%. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 22327.21%. Given that Nuwellis, Inc. has higher upside potential than Humacyte, Inc., analysts believe Nuwellis, Inc. is more attractive than Humacyte, Inc..

Humacyte, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.165, suggesting its less volatile than the S&P 500 by 116.484%.

Humacyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte, Inc. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.

Humacyte, Inc. quarterly revenues are $753K, which are smaller than Nuwellis, Inc. quarterly revenues of $2.2M. Humacyte, Inc.'s net income of -$17.5M is lower than Nuwellis, Inc.'s net income of $468K. Notably, Humacyte, Inc.'s price-to-earnings ratio is -- while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte, Inc. is 98.39x versus 0.55x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rockwell Medical, Inc. has a net margin of -2325.37% compared to Humacyte, Inc.'s net margin of -11.01%. Humacyte, Inc.'s return on equity of -- beat Rockwell Medical, Inc.'s return on equity of -17.16%.

Humacyte, Inc. has a consensus price target of $7.86, signalling upside risk potential of 627.51%. On the other hand Rockwell Medical, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 363.36%. Given that Humacyte, Inc. has higher upside potential than Rockwell Medical, Inc., analysts believe Humacyte, Inc. is more attractive than Rockwell Medical, Inc..

Humacyte, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rockwell Medical, Inc. has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.123%.

Humacyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rockwell Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte, Inc. pays -- of its earnings as a dividend. Rockwell Medical, Inc. pays out -- of its earnings as a dividend.

Humacyte, Inc. quarterly revenues are $753K, which are smaller than Rockwell Medical, Inc. quarterly revenues of $15.9M. Humacyte, Inc.'s net income of -$17.5M is lower than Rockwell Medical, Inc.'s net income of -$1.8M. Notably, Humacyte, Inc.'s price-to-earnings ratio is -- while Rockwell Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte, Inc. is 98.39x versus 0.37x for Rockwell Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Salarius Pharmaceuticals, Inc. has a net margin of -2325.37% compared to Humacyte, Inc.'s net margin of --. Humacyte, Inc.'s return on equity of -- beat Salarius Pharmaceuticals, Inc.'s return on equity of -316.09%.

Humacyte, Inc. has a consensus price target of $7.86, signalling upside risk potential of 627.51%. On the other hand Salarius Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 61220.73%. Given that Salarius Pharmaceuticals, Inc. has higher upside potential than Humacyte, Inc., analysts believe Salarius Pharmaceuticals, Inc. is more attractive than Humacyte, Inc..

Humacyte, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Salarius Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.225%.

Humacyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Salarius Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte, Inc. pays -- of its earnings as a dividend. Salarius Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Humacyte, Inc. quarterly revenues are $753K, which are larger than Salarius Pharmaceuticals, Inc. quarterly revenues of --. Humacyte, Inc.'s net income of -$17.5M is lower than Salarius Pharmaceuticals, Inc.'s net income of -$873.5K. Notably, Humacyte, Inc.'s price-to-earnings ratio is -- while Salarius Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte, Inc. is 98.39x versus -- for Salarius Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.